Weili Pan

No. 158, Shangtang Road
Hangzhou, 310014, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Immune cell phenotypes in the context of diabetic nephropathy: A Mendelian randomization analysis.

Immune cell phenotypes in the context of diabetic nephropathy: A Mendelian randomization analysis.

Journal: Medicine

Published: December 31, 2025

Superior efficacy and comparable safety of calcipotriol plus betamethasone dipropionate foam vs. ointment in Chinese patients with plaque psoriasis: A randomized phase 3 trial.

Superior efficacy and comparable safety of calcipotriol plus betamethasone dipropionate foam vs. ointment in Chinese patients with plaque psoriasis: A randomized phase 3 trial.

Journal: Chinese medical journal

Published: March 21, 2025

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial.

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial.

Journal: The Journal of dermatology

Published: February 08, 2025

Letter to the Editor on "Extended Treatment-dose Antibiotic Therapy vs Low-dose Prophylaxis for the Management of Recurrent Uncomplicated Urinary Tract Infections in Peri- and Postmenopausal Women".

Letter to the Editor on "Extended Treatment-dose Antibiotic Therapy vs Low-dose Prophylaxis for the Management of Recurrent Uncomplicated Urinary Tract Infections in Peri- and Postmenopausal Women".

Journal: Urology

Published: December 30, 2024

Efficacy and safety of the triple combination cream in Chinese patients with moderate to severe melasma: A multi-center, randomized, double-blind, three-arm, parallel-group, placebo-controlled clinical trial.

Efficacy and safety of the triple combination cream in Chinese patients with moderate to severe melasma: A multi-center, randomized, double-blind, three-arm, parallel-group, placebo-controlled clinical trial.

Journal: Chinese medical journal

Published: December 17, 2024

Correction to: Effcacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study.

Correction to: Effcacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study.

Journal: Advances in therapy

Published: November 09, 2024

Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab.

Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab.

Journal: Advances in therapy

Published: August 19, 2024

Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study.

Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study.

Journal: Advances in therapy

Published: June 18, 2024

Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial.

Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial.

Journal: The British journal of dermatology

Published: May 31, 2024

A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.

A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.

Journal: The British journal of dermatology

Published: September 26, 2023

Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension.

Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension.

Journal: Chinese medical journal

Published: June 24, 2023

A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis.

A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis.

Journal: International immunopharmacology

Published: May 31, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026